Aroa Biosurgery Limited (AROAF)

Market Cap	142.50M
Revenue (ttm)	48.00M
Net Income (ttm)	-2.16M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	109.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.3500
Previous Close	0.3500
Day's Range	0.3500 - 0.3500
52-Week Range	0.2439 - 0.4000
Beta	n/a
RSI	82.36
Earnings Date	Nov 25, 2025

About Altus Power

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Country: New Zealand
• Stock Exchange: OTCMKTS
• Ticker Symbol: AROAF

Financial Performance

In 2024, Aroa Biosurgery's revenue was 84.70 million, an increase of 22.63% compared to the previous year's 69.07 million. Losses were -3.81 million, -64.12% less than in 2023.